ArticleInternational urology and nephrology2025
Experience of nine south eastern European transplant centers with testicular cancer in kidney transplant recipients.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTesticular cancer (TC) is the most common type of cancer among young men aged 25 to 45. This study represents the first population study of TC in kidney transplant recipients (KTRs).
methodsWe conducted a multicentric, multinational, cross-sectional study across nine transplant centers in Croatia, Serbia, Montenegro, Slovenia, and Bosnia and Herzegovina. All KTRs over 18 years old who were regularly monitored at their transplant centers were included. Data were collected from electronic medical records at these centers.
resultsOut of the 4426 KTRs who participated in our study, six (0.14%) developed TC after KT. Two of these patients had a history of malignancy before KT, while four had a positive family history of malignancy. The median age at diagnosis of TC was 41 years. Follow-up time ranged from 1 to 14 years. Most of the patients underwent surgical treatment and half received adjuvant chemotherapy and/or radiotherapy. Four patients had seminoma and two had non-seminoma. In most cases, the immunosuppressive therapy was adjusted. Half of the patients maintained stable kidney allograft function after TC treatment. One patient died due to COVID-19 and two required chronic dialysis 8-9 years after their TC diagnosis and treatment.
conclusionsIn our study, TC occurred in the same age range as in the general population. A personal or family history of malignancy was identified as a significant risk factor. Outcomes for kidney allograft function and overall survival were excellent for patients whose disease was detected early and treated with orchiectomy. Switching from calcineurin to mTOR inhibitors also supported allograft survival.
Indexed as
Identifiers
40167983What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.